Department of Chemistry, Jinan University, Guangzhou 510632, China.
Department of Chemistry, Jinan University, Guangzhou 510632, China.
Acta Biomater. 2017 May;54:294-306. doi: 10.1016/j.actbio.2017.02.042. Epub 2017 Mar 4.
To reduce the side effects and enhance the anti-tumor activities of anticancer drugs in the clinic, the use of nano mesoporous materials, with mesoporous silica (MSN) being the best-studied, has become an effective method of drug delivery. In this study, we successfully synthesized mesoporous selenium (MSe) nanoparticles and first introduced them to the field of drug delivery. Loading MSe with doxorubicin (DOX) is mainly driven by the physical adsorption mechanism of the mesopores, and our results demonstrated that MSe could synergistically enhance the antitumor activity of DOX. Coating the surface of MSe@DOX with Human serum albumin (HSA) generated a unique redox-responsive nanoparticle (HSA-MSe@DOX) that demonstrated glutathione-dependent drug release, increased tumor-targeting effects and enhanced cellular uptake throug nanoparticle interact with SPARC in MCF-7 cells. In vitro, HSA-MSe@DOX prominently induced cancer cell toxicity by synergistically enhancing the effects of MSe and DOX. Moreover, HSA-MSe@DOX possessed tumor-targeting abilities in tumor-bearing nude mice and not only decreased the side effects associated with DOX, but also enhanced its antitumor activity. Therefore, HSA-MSe@DOX is a promising new drug that warrants further evaluation in the treatments of tumors.
To reduce the side effects and enhance the anti-tumor activities of anticancer drugs, we successfully synthesized mesoporous selenium (MSe) nanoparticles and first introduced them to the field of drug delivery. Loading MSe with doxorubicin (DOX) is mainly driven by the physical adsorption mechanism of the mesopores. Coating the surface of MSe@DOX with Human serum albumin (HSA) generated a unique redox-responsive nanoparticle (HSA-MSe@DOX) that demonstrated glutathione-dependent drug release, increased tumor-targeting effects and enhanced cellular uptake throug nanoparticle interact with SPARC in MCF-7 cells. In vitro and in vivo, HSA-MSe@DOX possessed tumor-targeting abilities and not only decreased the side effects associated with DOX, but also enhanced its antitumor activity. Therefore, HSA-MSe@DOX is a promising new drug that warrants further evaluation in the treatments of tumors.
为降低临床抗癌药物的副作用并提高其抗肿瘤活性，使用介孔纳米材料（以介孔硅 MSN 研究最多）已成为药物递送的有效方法。本研究成功合成了介孔硒（MSe）纳米粒子，并首次将其引入药物递送领域。载药主要通过介孔的物理吸附机制将 MSe 与阿霉素（DOX）结合，结果表明 MSe 可以协同增强 DOX 的抗肿瘤活性。通过人血清白蛋白（HSA）对 MSe@DOX 进行表面包覆，生成具有独特氧化还原响应的纳米粒子（HSA-MSe@DOX），该纳米粒子具有谷胱甘肽依赖性药物释放、增加肿瘤靶向作用以及通过纳米粒子与 MCF-7 细胞中 SPARC 的相互作用增强细胞摄取的特性。体外实验中，HSA-MSe@DOX 通过协同增强 MSe 和 DOX 的作用显著诱导癌细胞毒性。此外，HSA-MSe@DOX 在荷瘤裸鼠中具有肿瘤靶向能力，不仅降低了与 DOX 相关的副作用，还增强了其抗肿瘤活性。因此，HSA-MSe@DOX 是一种很有前途的新药，值得进一步研究用于肿瘤治疗。
为降低抗癌药物的副作用并提高其抗肿瘤活性，我们成功合成了介孔硒（MSe）纳米粒子，并首次将其引入药物递送领域。载药主要通过介孔的物理吸附机制将 MSe 与阿霉素（DOX）结合。通过人血清白蛋白（HSA）对 MSe@DOX 进行表面包覆，生成具有独特氧化还原响应的纳米粒子（HSA-MSe@DOX），该纳米粒子具有谷胱甘肽依赖性药物释放、增加肿瘤靶向作用以及通过纳米粒子与 MCF-7 细胞中 SPARC 的相互作用增强细胞摄取的特性。在体外和体内，HSA-MSe@DOX 均具有肿瘤靶向能力，不仅降低了与 DOX 相关的副作用，还增强了其抗肿瘤活性。因此，HSA-MSe@DOX 是一种很有前途的新药，值得进一步研究用于肿瘤治疗。
